Valuation: OliX Pharmaceuticals, Inc

Market Cap 3,034B 1.98B 1.73B 1.59B 1.48B 2.82B 189B 2.86B 19.12B 7.43B 92.78B 7.44B 7.28B 320B P/E 2026 *
-96.4x
P/E 2027 * -99.2x
Enterprise Value 3,034B 1.98B 1.73B 1.59B 1.48B 2.82B 189B 2.86B 19.12B 7.43B 92.78B 7.44B 7.28B 320B EV / Sales 2026 *
379x
EV / Sales 2027 * 276x
Free-Float
82.92%
Yield 2026 *
-
Yield 2027 * -
06-28 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development CI
06-04 OliX Pharmaceuticals, Inc announced that it has received KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
05-31 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
05-15 OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-31 Ollix Receives Patent Registration Decision from the United States Patent and Trademark Office CI
03-16 OliX Pharmaceuticals, Inc Reports Earnings Results for the Full Year Ended December 31, 2025 CI
02-07 Vect-Horus Reports CNS-Focused Research Collaboration with OliX Pharmaceuticals CI
12-02 Olix Pharmaceuticals receives milestone payment from L'Oréal RE
11-14 OliX Pharmaceuticals, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
27/08/25 OliX Pharmaceuticals, Inc announced that it has received KRW 115.002040047 billion in funding from a group of investors CI
14/08/25 OliX Pharmaceuticals, Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
15/05/25 OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
21/03/25 OliX Pharmaceuticals, Inc Reports Earnings Results for the Full Year Ended December 31, 2024 CI
1 day-4.78%
1 week+10.92%
Current month-4.05%
1 month+0.34%
3 months-8.96%
6 months+0.47%
Current year+6.34%
1 week 140,100
Extreme 140100
179,400
1 month 112,000
Extreme 112000
179,400
Current year 111,800
Extreme 111800
217,000
1 year 35,000
Extreme 35000
217,000
3 years 8,280
Extreme 8280
217,000
5 years 8,280
Extreme 8280
217,000
10 years 8,280
Extreme 8280
217,000
Manager TitleAgeSince
Chief Executive Officer 54 31/01/2010
Director of Finance/CFO 40 -
Corporate Officer/Principal 51 27/03/2022
Director TitleAgeSince
Director/Board Member 61 18/03/2019
Director/Board Member 55 18/03/2019
Chairman 54 31/01/2010
Date Insider Type Main position Quantity % Market Cap.
27/02/25Fiscal year

Director

30,000 0.1625%
27/02/25Fiscal year

Chief Technology Officer

8,000 0.0433%
Change 5-day change 1-year change 3-year change Capi.($)
-4.78%+10.92%+300.81%+865.09% 1.98B
-0.19%+5.55%+77.94%+135.65% 59.1B
+2.32%+5.03%+75.26%+92.31% 55.19B
+3.86%+6.93%-11.32%-10.57% 24.67B
+4.30%+7.95%+14.11%+440.44% 24.19B
+0.64%+7.14%+50.90%-1.05% 19.69B
-0.98%+7.74%+41.55%-28.68% 17.56B
0.00%+20.78%+186.15%+347.42% 16.22B
+4.91%+20.18%+48.55% - 14.84B
+3.50%+1.97%+21.02%+193.33% 14.04B
Average +1.35%+6.64%+80.50%+225.99% 24.75B
Weighted average by Cap. +1.70%+6.34%+61.36%+142.05%

Financials

2026 *2027 *
Net sales 8B 5.23M 4.57M 4.2M 3.91M 7.42M 498M 7.54M 50.41M 19.6M 245M 19.62M 19.2M 843M 11B 7.19M 6.28M 5.77M 5.38M 10.21M 684M 10.36M 69.31M 26.95M 336M 26.98M 26.4M 1.16B
Net income -31B -20.25M -17.71M -16.27M -15.17M -28.77M -1.93B -29.2M -195M -75.94M -948M -76.02M -74.39M -3.27B -30B -19.6M -17.13M -15.75M -14.68M -27.84M -1.87B -28.26M -189M -73.49M -917M -73.57M -71.99M -3.16B
Net Debt - -
Logo OliX Pharmaceuticals, Inc
OliX Pharmaceuticals, Inc. is a Korea-based company principally engaged in the research and development of new drugs for intractable diseases based on ribonucleic acid interference (RNAi) platform technologies. The Company’s product profile consists of OLX101, OLX102, OLX103, OLX104, OLX201, OLX301, OLX401 and others. These products are used for the treatment of hypertrophic scars and keloids, atopic dermatitis, androgenic alopecia, diabetic ulcer, age-related macular degeneration (AMD), idiopathic pulmonary fibrosis, neuropathic pain, liver fibrosis. In addition, these products are applied for skin brightening, anti-wrinkle and others. The Company operates its business within domestic market and to overseas markets.
Employees
-
Date Price Change Volume
03/07/26 ₩149,300.00 -4.78% 349,911
02/07/26 ₩156,800.00 -6.11% 385,651
01/07/26 ₩167,000.00 +7.33% 518,166
30/06/26 ₩155,600.00 -6.94% 401,264
29/06/26 ₩167,200.00 +24.22% 844,686
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A226950 Stock